Circulating MicroRNA-21 Is a Potential Diagnostic Biomarker in Gastric Cancer

Table 1

Association of miR-21 expression with clinicopathological features.

Variable		Serum miR-21		PBMC miR-21
Clinical stage
I	9	32.31 (22.88–54.12)	0.790	33.01 (22.35–53.63)	0.751
II	11	31.62 (21.14–50.12)		32.42 (21.05–51.79)
III	10	31.43 (22.31–49.33)		31.38 (21.31–49.98)
IV	18	30.82 (23.45–41.23)		30.19 (20.45–45.94)
Age
<35	8	31.77 (23.28–51.02)	0.812	30.33 (22.43–50.78)	0.892
35–50	10	29.67 (23.21–50.53)		28.66 (24.32–51.22)
51–65	18	30.25 (24.22–52.38)		30.66 (23.99–51.59)
>66	14	32.81 (25.88–53.62)		31.67 (22.98–54.11)
Gender
Male	24	29.95 (23.24–49.38)	0.844	28.66 (22.42–48.78)	0.789
Female	26	30.17 (22.66–50.19)		29.32 (23.16–50.68)
Lymphatic metastasis
Yes	27	29.99 (25.87–51.12)	0.678	31.54 (24.55–51.66)	0.643
No	23	30.23 (24.78–50.22)		32.11 (24.11–50.35)
Differentiation degree
Low	12	29.87 (24.68–49.88)	0.99	30.22 (23.33–51.66)	0.89
Middle	17	30.19 (24.98–50.86)		30.12 (23.02–51.76)
High	21	30.21 (25.56–51.25)		31.01 (24.45–51.87)
Surgery
Yes	24	30.55 (24.97–50.15)	0.551	31.44 (24.29–51.54)	0.521
No	26	29.78 (23.99–51.21)		30.22 (23.12–50.18)